We recently demonstrated that, in a small cohort of 40 patients scheduled for repeat PBx, Pentraxin 3 significantly outperformed PSA (AUC 0.92 vs. 0.55) in predicting the risk of being diagnosed with PCa (26). The gene discussed is KLK3; the disease is posterior cortical atrophy.